目的 研究加减知柏地黄丸治疗女童中枢性性早熟的疗效与雌激素受体（ER）α、β 基因多 态性之间的相关性。方法 选取 2017 年 7 月至 2020 年 1 月广东省妇幼保健院中医科门诊治疗的中枢性 性早熟女童，根据加减知柏地黄丸的疗效将患者分为有效组 60 例和无效组 20 例。应用聚合酶链反应⁃限 制性片段长度多态性（polymerise chain reaction⁃restriction fragment length polymorphism，PCR⁃RFLP）分析技术，检测两组女孩雌激素受体 α 基因 PvuⅡ和 XbaⅠ及受体 β 基因 RsaⅠ和 AluⅠ遗传多态性。结果 两组 ERα⁃PvuⅡ和 ERα⁃XbaⅠ基因多态性差异无统计学意义（P > 0.05）；两组 ERβ RsaⅠ与 ERβAluⅠ基因多态 性差异有统计学意义（P < 0.05）。结论 ERα⁃PvuⅡ与 ERα⁃XbaⅠ的基因多态性不影响加减知柏地黄丸 治疗女童中枢性性早熟的疗效，而ERβRsaⅠ与ERβAluⅠ不同的基因多态性则对疗效有影响。

Objective To study the correlation between the effect of Zhibaidihuang pills on central preco⁃ cious puberty in girls and the polymorphism of estrogen receptor（ER）α and β genes. Methods A total of 60 girls with central precocious puberty were selected from the outpatient department of traditional Chinese medicine of Guangdong Province Hospital for Women and Children Healthcare from July 2017 to January 2020. The patients were divided into effective group（n = 60）and ineffective group（n = 20）according to the effect of modified Zhibaidi⁃ huang pills. Polymerise chain reaction⁃restriction fragment length polymorphism（PCR⁃RFLP）was used to analyze the restriction fragment length. Genetic polymorphisms of estrogen receptor α genes Pvu Ⅱ and Xba I and receptor β genes RsaI and AluI were detected in the two groups of girls. Results There was no significant difference in ERα⁃Pvu II and ERα⁃XbaI gene polymorphisms between the effective group and the ineffective group（P > 0.05）. There were significant differences in ERβ RsaI and ERβ Alui gene polymorphisms between the effective group and the invalid group（P < 0.05）. Conclusion The genetic polymorphisms of ERα⁃PvuII and ERα⁃Xba I do not affect the efficacy of the treatment of girls with precocious puberty by modified Zhibaidihuang pills，but the different gene polymorphisms of Erβ⁃RsaI and Erβ⁃AluI do.